Related Experiment Videos
Hypotensive effect in the rat after oral prostacyclin (PGI2)
Prostaglandins, Leukotrienes, and Medicine
|April 1, 1985
Summary
Prostacyclin (PGI2) effectively reduces blood pressure in rats after oral intake. This hypotensive effect is attributed to PGI2, not its metabolite, 6-keto-PGF1 alpha.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Prostacyclin (PGI2) is a potent vasodilator with known cardiovascular effects.
- Understanding the oral bioavailability and efficacy of PGI2 is crucial for potential therapeutic applications.
Purpose of the Study:
- To investigate the dose-dependent hypotensive effects of orally administered Prostacyclin (PGI2) in conscious rats.
- To determine if the metabolite 6-keto-PGF1 alpha contributes to the blood pressure lowering effects of PGI2.
Main Methods:
- Oral administration of varying doses of PGI2 to normotensive and spontaneously hypertensive rats.
- Monitoring of mean systemic arterial pressure and heart rate.
- Administration of 6-keto-PGF1 alpha to assess its independent effect on blood pressure.
Main Results:
- PGI2 significantly lowered mean systemic arterial pressure in a dose-dependent manner in both rat models.
- The median effective dose (ED30) for PGI2 was 0.79 mg/kg in normotensive rats and 0.63 mg/kg in hypertensive rats.
- Heart rate remained unaffected, and 6-keto-PGF1 alpha did not alter blood pressure at 2 mg/kg p.o.
Conclusions:
- Oral administration of PGI2 effectively reduces blood pressure in conscious rats.
- The hypotensive action is mediated by PGI2 itself, not its metabolite 6-keto-PGF1 alpha.